

# Disease burden of pneumonia in Korean adults aged over 50 years stratified by age and underlying diseases

Jung Yeon Lee<sup>1</sup>, Chul Gyu Yoo<sup>2</sup>, Hyo-Jin Kim<sup>3</sup>, Ki Suck Jung<sup>4</sup>, and Kwang Ha Yoo<sup>5</sup>

<sup>1</sup>Department of Internal Medicine, Konkuk University Chungju Hospital, Chungju; <sup>2</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul; <sup>3</sup>Outcomes Research/Evidence Based Medicine Team, Market Access Department, Pfizer Pharmaceuticals Korea Ltd., Seoul; <sup>4</sup>Division of Pulmonary Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang; <sup>5</sup>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea

Korean J Intern Med 2014;29:764-773  
<http://dx.doi.org/10.3904/kjim.2014.29.6.764>

In the article cited above, Results part of abstract has some error. It must be modified KRW instead of US \$ as follow.

“In addition, the total cost for treatment of pneumonia was higher in the elderly compared to the non-elderly (KRW 2,088,190 vs. **KRW** 1,701,386,  $p < 0.001$ ). Those with an underlying disease had a higher CURB-65 score (1.26 vs. 0.68,  $p < 0.001$ ), were much older (mean age 71.24 vs. 64.24,  $p < 0.001$ ) and had a higher mortality rate than those without an underlying disease (3.5% [n = 20] vs. 1.7% [n = 2],  $p = 0.558$ ). The total per-capita medical fees were higher (KRW 2,074,520 vs. **KRW** 1,440,471,  $p < 0.001$ ) and hospital LOS was longer (mean 8.38 days vs. 6.42 days,  $p < 0.001$ ) in patients with underlying diseases compared to those without.”

We apologize for any inconvenience that this may have caused.